These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 31155438)
1. Metabolomics informs common patterns of molecular dysfunction across histologies of renal cell carcinoma. DiNatale RG; Sanchez A; Hakimi AA; Reznik E Urol Oncol; 2020 Oct; 38(10):755-762. PubMed ID: 31155438 [TBL] [Abstract][Full Text] [Related]
2. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma. Sun G; Zhang X; Liang J; Pan X; Zhu S; Liu Z; Armstrong CM; Chen J; Lin W; Liao B; Lin T; Huang R; Zhang M; Zheng L; Yin X; Nie L; Shen P; Zhao J; Zhang H; Dai J; Shen Y; Li Z; Liu J; Chen J; Liu J; Wang Z; Zhu X; Ni Y; Qin D; Yang L; Chen Y; Wei Q; Li X; Zhou Q; Huang H; Yao J; Chen N; Zeng H Clin Cancer Res; 2021 Mar; 27(6):1734-1743. PubMed ID: 33414138 [TBL] [Abstract][Full Text] [Related]
3. Metabolomics in renal cell carcinoma: From biomarker identification to pathomechanism insights. Chen YY; Hu HH; Wang YN; Liu JR; Liu HJ; Liu JL; Zhao YY Arch Biochem Biophys; 2020 Nov; 695():108623. PubMed ID: 33039388 [TBL] [Abstract][Full Text] [Related]
4. Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism. Leisz S; Schulz K; Erb S; Oefner P; Dettmer K; Mougiakakos D; Wang E; Marincola FM; Stehle F; Seliger B Oncotarget; 2015 May; 6(13):11395-406. PubMed ID: 25890500 [TBL] [Abstract][Full Text] [Related]
6. Integrated transcriptomic and metabolomic analysis shows that disturbances in metabolism of tumor cells contribute to poor survival of RCC patients. Popławski P; Tohge T; Bogusławska J; Rybicka B; Tański Z; Treviño V; Fernie AR; Piekiełko-Witkowska A Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):744-752. PubMed ID: 28012969 [TBL] [Abstract][Full Text] [Related]
7. Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies. Xiao Y; Meierhofer D Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357507 [TBL] [Abstract][Full Text] [Related]
8. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma. Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065 [TBL] [Abstract][Full Text] [Related]
9. Role of metabolomics-derived biomarkers to identify renal cell carcinoma: a comprehensive perspective of the past ten years and advancements. Gupta A; Nath K; Bansal N; Kumar M Expert Rev Mol Diagn; 2020 Jan; 20(1):5-18. PubMed ID: 31825678 [No Abstract] [Full Text] [Related]
10. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma. Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842 [TBL] [Abstract][Full Text] [Related]
11. (1)H NMR metabolomics analysis of renal cell carcinoma cells: Effect of VHL inactivation on metabolism. Cuperlovic-Culf M; Cormier K; Touaibia M; Reyjal J; Robichaud S; Belbraouet M; Turcotte S Int J Cancer; 2016 May; 138(10):2439-49. PubMed ID: 26620126 [TBL] [Abstract][Full Text] [Related]
12. Fumarate hydratase as a therapeutic target in renal cancer. Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123 [TBL] [Abstract][Full Text] [Related]
13. PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth. Abu Aboud O; Donohoe D; Bultman S; Fitch M; Riiff T; Hellerstein M; Weiss RH Am J Physiol Cell Physiol; 2015 Jun; 308(11):C890-8. PubMed ID: 25810260 [TBL] [Abstract][Full Text] [Related]
14. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review. Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391 [TBL] [Abstract][Full Text] [Related]
16. The genomics of renal cell carcinoma and its role in renal mass biopsy. Salami SS; George AK; Udager AM Curr Opin Urol; 2018 Jul; 28(4):383-391. PubMed ID: 29708949 [TBL] [Abstract][Full Text] [Related]
17. Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy. Wang Y; Zhang Y; Wang P; Fu X; Lin W Mol Cancer; 2020 Oct; 19(1):149. PubMed ID: 33054773 [TBL] [Abstract][Full Text] [Related]
19. Introduction to high throughput platforms in kidney cancer: Genomics, transcriptomics, and metabolomics urologic oncology: Seminars and original investigations. Hakimi AA Urol Oncol; 2020 Oct; 38(10):741. PubMed ID: 32753358 [No Abstract] [Full Text] [Related]